Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Open Access
- 24 July 2023
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 29 (8) , 2068-2078
Abstract
Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable ESCC. Patients received two neoadjuvant doses of adebrelimab followed by surgery. The primary endpoints were safety and feasibility; secondary endpoints included pathologic complete response (pCR) and OS. Our data showed the primary endpoints of safety and feasibility had been met. Common treatment-related adverse events were anorexia (32%) and fatigue (16%), without grade 3 or more adverse events. Of the 30 patients enrolled in the trial, 25 underwent successful resection without surgery delay and 24% had major pathologic responses including a pCR rate of 8%. The 2-year OS was 92%. Responsive patients had an immune-enriched tumor microenvironment phenotype, whereas nonresponsive patients had greater infiltration of cancer-associated fibroblasts at baseline. Clonotypic dynamics of pre-existing intratumoral T cells was a hallmark of responsive patients. These findings provide a rational for neoadjuvant anti-PD-L1 monotherapy as a therapeutic strategy for patients with resectable ESCC. ClinicalTrials.gov identifier: NCT04215471.Keywords
This publication has 51 references indexed in Scilit:
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerJournal of Clinical Oncology, 2020
- Learning from clinical trials of neoadjuvant checkpoint blockadeNature Medicine, 2020
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancersNature Medicine, 2020
- Neoadjuvant checkpoint blockade for cancer immunotherapyScience, 2020
- Clonal replacement of tumor-specific T cells following PD-1 blockadeNature Medicine, 2019
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerNew England Journal of Medicine, 2018
- Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatmentProceedings of the National Academy of Sciences, 2018
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer EvolutionCell, 2017
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapyNature, 2016
- Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysisThe Lancet Oncology, 2011